AMRI Names Senior Director, Analytical and Quality Services


ALBANY, N.Y. -- AMRI (NASDAQ: AMRI) announced today that Junan Guo, Ph.D. has joined the company as senior director, analytical and quality services. Dr. Guo fills the role vacated by Dr. Steven Hagen, who was promoted to vice president of pharmaceutical development and manufacturing in September 2008.

Dr. Guo will oversee all domestic analytical chemistry, preformulation and formulation, quality assurance and regulatory affairs efforts, including support related to early stage discovery and preclinical development, as well as the manufacturing of clinical trial materials, intermediates, and commercial active pharmaceutical ingredients. This includes developing analytical methods to test the purity of clinical trial candidates and commercial products manufactured at AMRI. He will provide leadership to a team of over 100 skilled scientists and quality professionals, and work closely with customers.

Prior to joining AMRI, Dr. Guo was director, analytical development at Patheon. There, he managed a scientific staff of about 170 individuals at multiple locations responsible for supporting contract dosage form development and manufacturing services. He began his tenure at Patheon in 1999 in the role of supervisor, analytical development. Prior to Patheon, he worked at Genpharm, Inc. in Toronto, Canada in the areas of analytical R&D and technology transfer.

Dr. Guo earned a Ph.D. in physical organic chemistry from The University of Western Ontario. He also holds a master's degree in medicinal chemistry from the Chinese Academy of Medical Sciences in Beijing, and a bachelor's degree in chemistry from Beijing Normal University.

AMRI Vice President, Pharmaceutical Development and Manufacturing Steven Hagen said, "We are pleased that Dr. Guo is joining our team as he has considerable CRO experience in pharmaceutical development and he is also trained in Lean Six Sigma techniques. These experiences will greatly aid our expansion plans and efficiency efforts across the AMRI development and manufacturing spectrum."

About AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Contacts:
Media:
AMRI Corporate Communications
Andrea Schulz, 518-512-2226
or
Investors:
Peter Jerome, 518-512-2220
AMRI Director of Investor Relations

All Topics